Bristol-Myers Squibb (BMY) Tops Q2 EPS by 13c
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $57.99 +2.28%
Revenue Growth %: -4.6%
Financial Fact:
Other (income)/expense: -224M
Today's EPS Names:
EPAC, SAR, KRUS, More
Revenue Growth %: -4.6%
Financial Fact:
Other (income)/expense: -224M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $1.93, $0.13 better than the analyst estimate of $1.80. Revenue for the quarter came in at $11.89 billion versus the consensus estimate of $11.44 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2022 EPS of $7.44-$7.74, versus the consensus of $7.46. Bristol-Myers Squibb sees FY2022 revenue of $46 billion, versus the consensus of $46.24 billion.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- Syra Health names Dr. Cori McMahon as fractional chief medical officer
- CCHH signs $50M data center services deal in Malaysia
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
